Related Experiment Video
Updated: Aug 6, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification
Oronzo Scarciolla1, Liborio Stuppia, Maria Vittoria De Angelis
1Dipartimento di Scienze Biomediche, Sezione di Genetica Medica, Università G. dAnnunzio, Via dei Vestini 35, Chieti-Pescara, 66013, Italy.
Neurogenetics
|July 26, 2006
Summary
Multiple Ligation-Dependent Probe Amplification (MLPA) effectively diagnoses Spinal Muscular Atrophy (SMA). This method identifies both affected individuals and healthy carriers, improving upon existing diagnostic techniques for SMA.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- Spinal Muscular Atrophy (SMA) is a severe autosomal recessive neuromuscular disorder.
- It is characterized by progressive muscle weakness and degeneration of motor neurons.
- Most SMA cases stem from mutations in the Survival Motor Neuron 1 (SMN1) gene.
Purpose of the Study:
- To evaluate the Multiple Ligation-Dependent Probe Amplification (MLPA) technique for SMA molecular diagnosis.
- To assess MLPA's ability to identify homozygous SMN1 deletions in affected patients.
- To determine MLPA's utility in detecting heterozygous SMN1 carriers.
Main Methods:
- The study utilized MLPA for molecular diagnosis of SMA.
- Analysis was performed on 19 affected patients and 57 at-risk individuals.
- MLPA distinguished between SMN1 deletion and conversion to SMN2.
Main Results:
- MLPA successfully detected homozygous SMN1 absence in all investigated SMA patients.
- The technique differentiated SMN1 deletions from SMN2 conversions based on peak sizes.
- MLPA identified heterozygous SMN1 absence in 33 of 57 at-risk relatives, confirming carrier status.
Conclusions:
- MLPA is a valuable tool for the molecular diagnosis of Spinal Muscular Atrophy.
- This method efficiently identifies both SMA patients and asymptomatic healthy carriers.
- MLPA offers an easy, cost-effective, and high-throughput solution for SMA genetic testing.
